After Weight Loss Surgery | NYU Langone Health
Get information from NYU Langone’s Weight Management Program experts about what to expect after weight loss surgery.
After Your Child’s Hospital Stay | NYU Langone Health
We help you prepare for your child’s discharge from Hassenfeld Children’s Hospital at NYU Langone.
After Your Child’s Surgery | NYU Langone Health
We help you know what to expect after your child has surgery at Hassenfeld Children’s Hospital at NYU Langone.
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current survival rates. The trial will eliminate chemotherapy for low risk patients who are likely cured with surgery and will observe the salvage rates among those who recur.Low risk patients are defined as Stage I patients, ages 0 – 50 years old. Since the trial is enrolling patients from pediatric oncology, gynecologic oncology and genito-urinary oncology (testicular cancer) the relevant staging criteria can be found in Appendices II (COG), III (FIGO), IV (AJCC) and V (IGCCC [International Germ Cell Consensus Classification]). The low risk arm will have two strata. One strata will includepatients with an ovarian pure immature teratoma: COG Stage I (FIGO Stage IA and IB), Grade 2 or 3 with a maximum alpha fetoprotein (a-FP) of 1,000 ng/mL. The other low risk strata will be comprised of patients with COG Stage I (FIGO Stage IA and B; AJCC Stage IA and B) germ cell tumors at any extracranial site (testes, ovary, extragonadal) that have at least one malignant histology, defined as embryonal carcinoma, choriocarcinoma or yolk sac tumor. Patients with pure seminoma or dysgerminoma are excluded from this trial. Low risk patients who recur may receive treatment, if eligible, on the appropriate standard risk arm.Among standard risk patients the trial will evaluate whether cisplatin, which is the standard-of-care in COG, can be replaced with a less toxic alternative platin analogue, carboplatin. The standard risk arm will be divided into 2 age-based strata: (1) Standard Risk 1 (SR1) arm, which includes patients up to 11 years of age with COG Stage II - IV ovarian, testicular or extragonadal GCT and (2) Standard Risk 2 (SR2) arm, which includes patients between 11 and 25 years of age with COG Stage II – III (FIGO Stage IC, II and III) ovarian, COG Stage II extragonadal and testicular, COG Stage II – IV with IGCCC good risk disease.SR1 patients will be randomized to receive either 4 cycles of PEb (cisplatin, etoposide and bleomycin) or 4 cycles of CEb (carboplatin, etoposide and bleomycin). SR2 patients will be randomized to receive either 3 cycles of BEP (cisplatin, etoposide and bleomycin) or 3 cycles of BEC (carboplatin, etoposide and bleomycin). Bleomycin will be administered once per cycle for a total of 4 doses in SR1 patients versusweekly for a total of 9 doses in SR2 patients.Several corollary studies, including evaluation of toxicities (including patient-reported outcomes), pharmacogenetic analysis of adverse events, evaluation of a new miRNA diagnostic and prognostic test and molecular pathway analysis of pediatric, adolescent and young adult GCT are important components of this clinical trial.
AGCT1532: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Bleomycin, Etoposide, Cisplatin (BEP) administered 3-weekly x 4 remains standard 1st line chemotherapy for intermediate- and poor-risk metastatic germ cell tumours (GCTs). Cure rates are over 90% for good-risk disease, 85% with intermediate-risk, and about 70% for poor-risk disease. Previous strategies to improve first-line chemotherapy have failed to improve cure rates and were more toxic than BEP. New strategies are needed for patients with intermediate and poor-risk disease. BEP is accelerated by cycling Cisplatin and etoposide 2-weekly instead of 3-weekly. The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) is conducting a trial comparing accelerated BEP with standard BEP. The aim of this study is to determine if accelerated BEP is superior to standard BEP as first-line chemotherapy for intermediate and poor risk metastatic GCTs.
Aging Skin | NYU Langone Health
Dermatologists and surgeons at NYU Langone offer injections, laser therapy, and cosmetic surgery to improve the appearance of aging skin.
AHCRN Registry: Characterizing Patient Populations in the Adult Hydrocephalus Clinical Research Network (AHCRN)
The AHCRN Registry has been developed to obtain data about hydrocephalus patientevents, treatments and outcomes from the network Clinical Centers, and to create a database to be used by AHCRN investigators. The ongoing maintenance of the Registry serves two main purposes: (1) it will help investigators understand the variability, progression, and current treatment practices for hydrocephalus in adults, with an ultimate goal of better guiding and assessing therapeutic intervention and providing recommendations on patient care and; (2) it will provide pilot and descriptive data necessary for hypothesis generation and study design (e.g., preliminary power analyses, recruitment projections) for studies under development by the AHCRN. This multi-institutional database will be useful for tracking trends in hydrocephalus over time. The Registry will be an invaluable resource to the AHCRN and will help stimulate new research protocols, identify potential need for future expansion of the network to incorporate additional patient populations, and provide a descriptive understanding of adults with hydrocephalus cared for within the network.
AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
The primary objective is to compare the PFS of patients with early-stage cHL treated through aresponse-adapted design with either standard therapy or with an IO approach (brentuximab vedotin andnivolumab). Patients will be randomized to standard chemotherapy versus IO therapy following initialresponse assessment by PET/CT after two courses of ABVD. All will be stratified as favorable orunfavorable based on initial disease risk features, and those who are PET2 positive (defined as 5 PointScore, 5PS 4 or 5) will receive involved site radiotherapy (ISRT). Overall, RT exposure will be reducedcompared to prior COG HL trials but within the standard of care per National Comprehensive CancerNetwork (NCCN) pediatric lymphoma guidelines.The study expects to enroll 1875 patients over 5 years of accrual, for an estimated 1782 evaluable patients (PET2negative/rapid early responder [RER] n = 1514; PET2 positive/slow-early responder [SER] n = 268). Byexamining both shorter-term PFS and longer-term OS (12-year), and by prospectively collecting detaileddata on toxicity outcomes, this protocol will be practice changing for both pediatric and adult patientswith cHL and will ultimately define the role of an IO approach in the management of early-stage HL.This is a randomized trial comparing an IO approach with or without radiation therapy to a standard chemotherapy approach with or without radiation therapy in early stage cHL. All patients will be stratified by favorable vs. unfavorable features at studyenrollment. Patients are considered unfavorable if they have one or more of the following factors: (1) large mediastinal mass (> 10 cm by CT or 1/3 max chest diameter by CXR), (2) > 3 nodal sites, (3) B symptoms with ESR > 30, (4) ESR > 50 without B symptoms, and (5) age > 50 years. All patients will receive 2 cycles of ABVD chemotherapy. Subsequently, a rapidcentral review will be performed to determine early response assessment (PET2),which will be utilized to randomize patients to receive either conventionalchemotherapy or an IO approach with nivolumab and brentuximab vedotin. If a patientis deemed to not meet study eligibility staging criteria at the time of PET2 centralreview, the patient will be removed from protocol therapy. All SER patients (5PS 4, 5)will receive involved site radiation therapy (ISRT). Following randomization, thepatient may be assigned to one of the following treatment arms:• Arm A (Favorable RER, Standard Therapy): ABVD x 2• Arm B (Favorable RER, IO Therapy): Brentuximab vedotin + Nivolumab x 4 Arm C (Favorable SER, Standard Therapy): eBEACOPP x 2, ISRT• Arm D (Favorable SER, IO Therapy): Brentuximab vedotin + Nivolumab x 4, ISRT• Arm E (Unfavorable RER, Standard Therapy): AVD x 4• Arm F (Unfavorable RER, IO Therapy): Brentuximab vedotin + Nivolumab x 4• Arm G (Unfavorable SER, Standard Therapy): eBEACOPP x 2, ISRT• Arm H (Unfavorable SER, IO Therapy): Brentuximab vedotin + Nivolumab x 4, ISRT
AIDS-Related Lymphoma | NYU Langone Health
Doctors at Perlmutter Cancer Center provide expert care for people who have AIDS-related lymphoma, a group of cancers that begin in white blood cells.
Airway Abnormality Services for Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone offer advanced diagnostic tools and treatments for airway abnormalities in children.